FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100048317> ?p ?o ?g. }

• W2100048317 abstract "Abstract Background The aim of this study was to explore the effects of HCV co-infection on virological effectiveness and on CD4+ T-cell recovery in patients with an early and sustained virological response after HAART. Methods We performed a longitudinal analysis of 3,262 patients from the MASTER cohort, who started HAART from 2000 to 2008. Patients were stratified into 6 groups by HCV status and type of anchor class. The early virological outcome was the achievement of HIV RNA <500 copies/ml 4–8 months after HAART initiation. Time to virological response was also evaluated by Kaplan-Meier analysis. The main outcome measure of early immunological response was the achievement of CD4+ T-cell increase by ≥100/mm 3 from baseline to month 4–8 in virological responder patients. Late immunological outcome was absolute variation of CD4+ T-cell count with respect to baseline up to month 24. Multivariable analysis (ANCOVA) investigated predictors for this outcome. Results The early virological response was higher in HCV Ab-negative than HCV Ab-positive patients prescribed PI/r (92.2% versus 88%; p = 0.01) or NNRTI (88.5% versus 84.7%; p = 0.06). HCV Ab-positive serostatus was a significant predictor of a delayed virological suppression independently from other variables, including types of anchor class. Reactivity for HCV antibodies was associated with a lower probability of obtaining ≥100/mm 3 CD4+ increase within 8 months from HAART initiation in patients treated with PI/r (62.2% among HCV Ab-positive patients versus 70.9% among HCV Ab-negative patients; p = 0.003) and NNRTI (63.7% versus 74.7%; p < 0.001). Regarding late CD4+ increase, positive HCV Ab appeared to impair immune reconstitution in terms of absolute CD4+ T-cell count increase both in patients treated with PI/r ( p = 0.013) and in those treated with NNRTI ( p = 0.002). This was confirmed at a multivariable analysis up to 12 months of follow-up. Conclusions In this large cohort, HCV Ab reactivity was associated with an inferior virological outcome and an independent association between HCV Ab-positivity and smaller CD4+ increase was evident up to 12 months of follow-up. Although the difference in CD4+ T-cell count was modest, a stricter follow-up and optimization of HAART strategy appear to be important in HIV patients co-infected by HCV. Moreover, our data support anti-HCV treatment leading to HCV eradication as a means to facilitate the achievement of the viro-immunological goals of HAART." @default.
• W2100048317 created "2016-06-24" @default.
• W2100048317 creator A5029829647 @default.
• W2100048317 creator A5031505042 @default.
• W2100048317 creator A5034814001 @default.
• W2100048317 creator A5038369659 @default.
• W2100048317 creator A5040761453 @default.
• W2100048317 creator A5041785868 @default.
• W2100048317 creator A5042651024 @default.
• W2100048317 creator A5052546170 @default.
• W2100048317 creator A5053242558 @default.
• W2100048317 creator A5054162674 @default.
• W2100048317 creator A5071994945 @default.
• W2100048317 creator A5074037938 @default.
• W2100048317 creator A5074373099 @default.
• W2100048317 creator A5085992339 @default.
• W2100048317 date "2012-06-15" @default.
• W2100048317 modified "2023-10-16" @default.
• W2100048317 title "Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received" @default.
• W2100048317 cites W1532561425 @default.
• W2100048317 cites W1597248718 @default.
• W2100048317 cites W1971370475 @default.
• W2100048317 cites W1984948687 @default.
• W2100048317 cites W1987491896 @default.
• W2100048317 cites W1990165995 @default.
• W2100048317 cites W1990521947 @default.
• W2100048317 cites W2002301737 @default.
• W2100048317 cites W2018253571 @default.
• W2100048317 cites W2026798367 @default.
• W2100048317 cites W2030639603 @default.
• W2100048317 cites W2053456104 @default.
• W2100048317 cites W2068502481 @default.
• W2100048317 cites W2069776389 @default.
• W2100048317 cites W2075790861 @default.
• W2100048317 cites W2089836296 @default.
• W2100048317 cites W2103268871 @default.
• W2100048317 cites W2104430490 @default.
• W2100048317 cites W2108247692 @default.
• W2100048317 cites W2119222528 @default.
• W2100048317 cites W2140606947 @default.
• W2100048317 cites W2140859072 @default.
• W2100048317 cites W2144194933 @default.
• W2100048317 cites W2144361427 @default.
• W2100048317 cites W2156380404 @default.
• W2100048317 cites W2158628116 @default.
• W2100048317 cites W2160132227 @default.
• W2100048317 cites W2160997908 @default.
• W2100048317 cites W2166096447 @default.
• W2100048317 cites W2167035059 @default.
• W2100048317 doi "https://doi.org/10.1186/1742-6405-9-18" @default.
• W2100048317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3409064" @default.
• W2100048317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22703595" @default.
• W2100048317 hasPublicationYear "2012" @default.
• W2100048317 type Work @default.
• W2100048317 sameAs 2100048317 @default.
• W2100048317 citedByCount "10" @default.
• W2100048317 countsByYear W21000483172013 @default.
• W2100048317 countsByYear W21000483172014 @default.
• W2100048317 countsByYear W21000483172015 @default.
• W2100048317 countsByYear W21000483172016 @default.
• W2100048317 countsByYear W21000483172017 @default.
• W2100048317 countsByYear W21000483172018 @default.
• W2100048317 countsByYear W21000483172022 @default.
• W2100048317 crossrefType "journal-article" @default.
• W2100048317 hasAuthorship W2100048317A5029829647 @default.
• W2100048317 hasAuthorship W2100048317A5031505042 @default.
• W2100048317 hasAuthorship W2100048317A5034814001 @default.
• W2100048317 hasAuthorship W2100048317A5038369659 @default.
• W2100048317 hasAuthorship W2100048317A5040761453 @default.
• W2100048317 hasAuthorship W2100048317A5041785868 @default.
• W2100048317 hasAuthorship W2100048317A5042651024 @default.
• W2100048317 hasAuthorship W2100048317A5052546170 @default.
• W2100048317 hasAuthorship W2100048317A5053242558 @default.
• W2100048317 hasAuthorship W2100048317A5054162674 @default.
• W2100048317 hasAuthorship W2100048317A5071994945 @default.
• W2100048317 hasAuthorship W2100048317A5074037938 @default.
• W2100048317 hasAuthorship W2100048317A5074373099 @default.
• W2100048317 hasAuthorship W2100048317A5085992339 @default.
• W2100048317 hasBestOaLocation W21000483171 @default.
• W2100048317 hasConcept C126322002 @default.
• W2100048317 hasConcept C142462285 @default.
• W2100048317 hasConcept C203014093 @default.
• W2100048317 hasConcept C2776535787 @default.
• W2100048317 hasConcept C3013748606 @default.
• W2100048317 hasConcept C71924100 @default.
• W2100048317 hasConcept C72563966 @default.
• W2100048317 hasConcept C90924648 @default.
• W2100048317 hasConceptScore W2100048317C126322002 @default.
• W2100048317 hasConceptScore W2100048317C142462285 @default.
• W2100048317 hasConceptScore W2100048317C203014093 @default.
• W2100048317 hasConceptScore W2100048317C2776535787 @default.
• W2100048317 hasConceptScore W2100048317C3013748606 @default.
• W2100048317 hasConceptScore W2100048317C71924100 @default.
• W2100048317 hasConceptScore W2100048317C72563966 @default.
• W2100048317 hasConceptScore W2100048317C90924648 @default.
• W2100048317 hasIssue "1" @default.
• W2100048317 hasLocation W21000483171 @default.
• W2100048317 hasLocation W21000483172 @default.
• W2100048317 hasLocation W21000483173 @default.
• W2100048317 hasLocation W21000483174 @default.

• next